Mass treatment with azithromycin for trachoma: when is one round enough? Results from the PRET Trial in the Gambia.
<h4>Background</h4>The World Health Organization has recommended three rounds of mass drug administration (MDA) with antibiotics in districts where the prevalence of follicular trachoma (TF) is ≥10% in children aged 1-9 years, with treatment coverage of at least 80%. For districts at 5-1...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2013-01-01
|
| Series: | PLoS Neglected Tropical Diseases |
| Online Access: | https://doi.org/10.1371/journal.pntd.0002115 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849722216511438848 |
|---|---|
| author | Emma M Harding-Esch Ansumana Sillah Tansy Edwards Sarah E Burr John D Hart Hassan Joof Mass Laye Pateh Makalo Ahmed Manjang Sandra Molina Isatou Sarr-Sissoho Thomas C Quinn Tom Lietman Martin J Holland David Mabey Sheila K West Robin Bailey Partnership for Rapid Elimination of Trachoma (PRET) study group |
| author_facet | Emma M Harding-Esch Ansumana Sillah Tansy Edwards Sarah E Burr John D Hart Hassan Joof Mass Laye Pateh Makalo Ahmed Manjang Sandra Molina Isatou Sarr-Sissoho Thomas C Quinn Tom Lietman Martin J Holland David Mabey Sheila K West Robin Bailey Partnership for Rapid Elimination of Trachoma (PRET) study group |
| author_sort | Emma M Harding-Esch |
| collection | DOAJ |
| description | <h4>Background</h4>The World Health Organization has recommended three rounds of mass drug administration (MDA) with antibiotics in districts where the prevalence of follicular trachoma (TF) is ≥10% in children aged 1-9 years, with treatment coverage of at least 80%. For districts at 5-10% TF prevalence it was recommended that TF be assessed in 1-9 year olds in each community within the district, with three rounds of MDA provided to any community where TF≥10%. Worldwide, over 40 million people live in districts whose TF prevalence is estimated to be between 5 and 10%. The best way to treat these districts, and the optimum role of testing for infection in deciding whether to initiate or discontinue MDA, are unknown.<h4>Methods</h4>In a community randomized trial with a factorial design, we randomly assigned 48 communities in four Gambian districts, in which the prevalence of trachoma was known or suspected to be above 10%, to receive annual mass treatment with expected coverage of 80-89% ("Standard"), or to receive an additional visit in an attempt to achieve coverage of 90% or more ("Enhanced"). The same 48 communities were randomised to receive mass treatment annually for three years ("3×"), or to have treatment discontinued if Chlamydia trachomatis (Ct) infection was not detected in a sample of children in the community after mass treatment (stopping rule("SR")). Primary outcomes were the prevalence of TF and of Ct infection in 0-5 year olds at 36 months.<h4>Results</h4>The baseline prevalence of TF and of Ct infection in the target communities was 6.5% and 0.8% respectively. At 36 months the prevalence of TF was 2.8%, and that of Ct infection was 0.5%. No differences were found between the arms in TF or Ct infection prevalence either at baseline (Standard-3×: TF 5.6%, Ct 0.7%; Standard-SR: TF 6.1%, Ct 0.2%; Enhanced-3×: TF 7.4%, Ct 0.9%; and Enhanced-SR: TF 6.2%, Ct 1.2%); or at 36 months (Standard-3×: TF 2.3%, Ct 1.0%; Standard-SR TF 2.5%, Ct 0.2%; Enhanced-3× TF 3.0%, Ct 0.2%; and Enhanced-SR TF 3.2%, Ct 0.7% ). The implementation of the stopping rule led to treatment stopping after one round of MDA in all communities in both SR arms. Mean treatment coverage of children aged 0-9 in communities randomised to standard treatment was 87.7% at baseline and 84.8% and 88.8% at one and two years, respectively. Mean coverage of children in communities randomized to enhanced treatment was 90.0% at baseline and 94.2% and 93.8% at one and two years, respectively. There was no evidence of any difference in TF or Ct prevalence at 36 months resulting from enhanced coverage or from one round of MDA compared to three.<h4>Conclusions</h4>The Gambia is close to the elimination target for active trachoma. In districts prioritised for three MDA rounds, one round of MDA reduced active trachoma to low levels and Ct infection was not detectable in any community. There was no additional benefit to giving two further rounds of MDA. Programmes could save scarce resources by determining when to initiate or to discontinue MDA based on testing for Ct infection, and one round of MDA may be all that is necessary in some settings to reduce TF below the elimination threshold. |
| format | Article |
| id | doaj-art-090ce82b92b74c30b5a1adf0af0bcdb6 |
| institution | DOAJ |
| issn | 1935-2727 1935-2735 |
| language | English |
| publishDate | 2013-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS Neglected Tropical Diseases |
| spelling | doaj-art-090ce82b92b74c30b5a1adf0af0bcdb62025-08-20T03:11:25ZengPublic Library of Science (PLoS)PLoS Neglected Tropical Diseases1935-27271935-27352013-01-0176e211510.1371/journal.pntd.0002115Mass treatment with azithromycin for trachoma: when is one round enough? Results from the PRET Trial in the Gambia.Emma M Harding-EschAnsumana SillahTansy EdwardsSarah E BurrJohn D HartHassan JoofMass LayePateh MakaloAhmed ManjangSandra MolinaIsatou Sarr-SissohoThomas C QuinnTom LietmanMartin J HollandDavid MabeySheila K WestRobin BaileyPartnership for Rapid Elimination of Trachoma (PRET) study group<h4>Background</h4>The World Health Organization has recommended three rounds of mass drug administration (MDA) with antibiotics in districts where the prevalence of follicular trachoma (TF) is ≥10% in children aged 1-9 years, with treatment coverage of at least 80%. For districts at 5-10% TF prevalence it was recommended that TF be assessed in 1-9 year olds in each community within the district, with three rounds of MDA provided to any community where TF≥10%. Worldwide, over 40 million people live in districts whose TF prevalence is estimated to be between 5 and 10%. The best way to treat these districts, and the optimum role of testing for infection in deciding whether to initiate or discontinue MDA, are unknown.<h4>Methods</h4>In a community randomized trial with a factorial design, we randomly assigned 48 communities in four Gambian districts, in which the prevalence of trachoma was known or suspected to be above 10%, to receive annual mass treatment with expected coverage of 80-89% ("Standard"), or to receive an additional visit in an attempt to achieve coverage of 90% or more ("Enhanced"). The same 48 communities were randomised to receive mass treatment annually for three years ("3×"), or to have treatment discontinued if Chlamydia trachomatis (Ct) infection was not detected in a sample of children in the community after mass treatment (stopping rule("SR")). Primary outcomes were the prevalence of TF and of Ct infection in 0-5 year olds at 36 months.<h4>Results</h4>The baseline prevalence of TF and of Ct infection in the target communities was 6.5% and 0.8% respectively. At 36 months the prevalence of TF was 2.8%, and that of Ct infection was 0.5%. No differences were found between the arms in TF or Ct infection prevalence either at baseline (Standard-3×: TF 5.6%, Ct 0.7%; Standard-SR: TF 6.1%, Ct 0.2%; Enhanced-3×: TF 7.4%, Ct 0.9%; and Enhanced-SR: TF 6.2%, Ct 1.2%); or at 36 months (Standard-3×: TF 2.3%, Ct 1.0%; Standard-SR TF 2.5%, Ct 0.2%; Enhanced-3× TF 3.0%, Ct 0.2%; and Enhanced-SR TF 3.2%, Ct 0.7% ). The implementation of the stopping rule led to treatment stopping after one round of MDA in all communities in both SR arms. Mean treatment coverage of children aged 0-9 in communities randomised to standard treatment was 87.7% at baseline and 84.8% and 88.8% at one and two years, respectively. Mean coverage of children in communities randomized to enhanced treatment was 90.0% at baseline and 94.2% and 93.8% at one and two years, respectively. There was no evidence of any difference in TF or Ct prevalence at 36 months resulting from enhanced coverage or from one round of MDA compared to three.<h4>Conclusions</h4>The Gambia is close to the elimination target for active trachoma. In districts prioritised for three MDA rounds, one round of MDA reduced active trachoma to low levels and Ct infection was not detectable in any community. There was no additional benefit to giving two further rounds of MDA. Programmes could save scarce resources by determining when to initiate or to discontinue MDA based on testing for Ct infection, and one round of MDA may be all that is necessary in some settings to reduce TF below the elimination threshold.https://doi.org/10.1371/journal.pntd.0002115 |
| spellingShingle | Emma M Harding-Esch Ansumana Sillah Tansy Edwards Sarah E Burr John D Hart Hassan Joof Mass Laye Pateh Makalo Ahmed Manjang Sandra Molina Isatou Sarr-Sissoho Thomas C Quinn Tom Lietman Martin J Holland David Mabey Sheila K West Robin Bailey Partnership for Rapid Elimination of Trachoma (PRET) study group Mass treatment with azithromycin for trachoma: when is one round enough? Results from the PRET Trial in the Gambia. PLoS Neglected Tropical Diseases |
| title | Mass treatment with azithromycin for trachoma: when is one round enough? Results from the PRET Trial in the Gambia. |
| title_full | Mass treatment with azithromycin for trachoma: when is one round enough? Results from the PRET Trial in the Gambia. |
| title_fullStr | Mass treatment with azithromycin for trachoma: when is one round enough? Results from the PRET Trial in the Gambia. |
| title_full_unstemmed | Mass treatment with azithromycin for trachoma: when is one round enough? Results from the PRET Trial in the Gambia. |
| title_short | Mass treatment with azithromycin for trachoma: when is one round enough? Results from the PRET Trial in the Gambia. |
| title_sort | mass treatment with azithromycin for trachoma when is one round enough results from the pret trial in the gambia |
| url | https://doi.org/10.1371/journal.pntd.0002115 |
| work_keys_str_mv | AT emmamhardingesch masstreatmentwithazithromycinfortrachomawhenisoneroundenoughresultsfromtheprettrialinthegambia AT ansumanasillah masstreatmentwithazithromycinfortrachomawhenisoneroundenoughresultsfromtheprettrialinthegambia AT tansyedwards masstreatmentwithazithromycinfortrachomawhenisoneroundenoughresultsfromtheprettrialinthegambia AT saraheburr masstreatmentwithazithromycinfortrachomawhenisoneroundenoughresultsfromtheprettrialinthegambia AT johndhart masstreatmentwithazithromycinfortrachomawhenisoneroundenoughresultsfromtheprettrialinthegambia AT hassanjoof masstreatmentwithazithromycinfortrachomawhenisoneroundenoughresultsfromtheprettrialinthegambia AT masslaye masstreatmentwithazithromycinfortrachomawhenisoneroundenoughresultsfromtheprettrialinthegambia AT patehmakalo masstreatmentwithazithromycinfortrachomawhenisoneroundenoughresultsfromtheprettrialinthegambia AT ahmedmanjang masstreatmentwithazithromycinfortrachomawhenisoneroundenoughresultsfromtheprettrialinthegambia AT sandramolina masstreatmentwithazithromycinfortrachomawhenisoneroundenoughresultsfromtheprettrialinthegambia AT isatousarrsissoho masstreatmentwithazithromycinfortrachomawhenisoneroundenoughresultsfromtheprettrialinthegambia AT thomascquinn masstreatmentwithazithromycinfortrachomawhenisoneroundenoughresultsfromtheprettrialinthegambia AT tomlietman masstreatmentwithazithromycinfortrachomawhenisoneroundenoughresultsfromtheprettrialinthegambia AT martinjholland masstreatmentwithazithromycinfortrachomawhenisoneroundenoughresultsfromtheprettrialinthegambia AT davidmabey masstreatmentwithazithromycinfortrachomawhenisoneroundenoughresultsfromtheprettrialinthegambia AT sheilakwest masstreatmentwithazithromycinfortrachomawhenisoneroundenoughresultsfromtheprettrialinthegambia AT robinbailey masstreatmentwithazithromycinfortrachomawhenisoneroundenoughresultsfromtheprettrialinthegambia AT partnershipforrapideliminationoftrachomapretstudygroup masstreatmentwithazithromycinfortrachomawhenisoneroundenoughresultsfromtheprettrialinthegambia |